Related Experiment Video
Updated: Jun 18, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
Limiting activity at beta1-subunit-containing GABAA receptor subtypes reduces ataxia
Kelvin W Gee1, Minhtam B Tran, Derk J Hogenkamp
1Department of Pharmacology, School of Medicine, University of California, Irvine, CA 92697, USA. kwgee@uci.edu
New nonbenzodiazepine drugs targeting GABA(A) receptors show promise for anxiolytic effects. By selectively modulating specific receptor subunits, these compounds may reduce sedative side effects, offering a safer therapeutic approach.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- GABA(A) receptor (R) positive allosteric modulators (PAMs) targeting beta(2)- and/or beta(3)-subunits over beta(1)-subunits are known, often as nonbenzodiazepines (nonBZs).
- These "beta(2/3)-selective" GABA(A)R PAMs generally exhibit anxiolytic efficacy with fewer sedative and ataxic effects compared to traditional benzodiazepines (BZs).
Purpose of the Study:
- To investigate an enantiomeric pair of nonBZ GABA(A)R PAMs with differential beta-subunit selectivity.
- To test the hypothesis that ataxia is correlated with the degree of modulation at beta(1)-subunit-containing GABA(A)Rs.
Main Methods:
- Electrophysiological assays to measure GABA(A)R modulation.
- Pharmacokinetic studies to assess drug distribution and metabolism.
- Behavioral assays in animal models to evaluate anxiolytic and ataxic effects.
Main Results:
- The tested enantiomeric pair demonstrated differential beta-subunit isoform selectivity.
- Comparison with other selective and non-selective GABA(A)R PAMs supported the hypothesis linking beta(1)-subunit modulation to ataxia.
Conclusions:
- Reduced or eliminated activity at beta(1)-subunit-containing GABA(A)Rs offers a strategy for developing anxioselective PAMs.
- This approach could yield drugs with benzodiazepine-like anxiolytic efficacy but improved safety profiles regarding sedation and ataxia.
More Related Videos
08:04Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
07:51Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors
Published on: November 14, 2014
Related Concept Videos
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Drugs Acting on Autonomic Ganglia: Blockers
Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Drugs Affecting Neurotransmitter Release or Uptake